Downregulation of HER2 levels is a potential therapeutic target and has been demonstrated within breast cancer cells via a luciferase reporter assay whereby stabilization of the HER2 promoter G4 structure downregulated HER2 expression at both the mRNA and protein levels (148). Here, ERBB2 is linked to breast carcinoma.